In April 2025, Precision Neuroscience quietly made history. Its cortical interface device, codenamed Layer 7, received FDA 510(k) clearance for commercial use with implantation durations of up to 30 days. It was the first commercial FDA clearance ever granted for a cortical brain-computer interface device. Then in December 2025, the FDA approved Flow Neuroscience’s FL-100, the first prescription at-home brain stimulation device for major depressive disorder.
While the world watches Neuralink, the competitors are shipping.
The global brain-computer interface market reached $3.2 billion in 2026, according to BCI Intel’s 2026 annual industry report. That is a 14% increase from $2.8 billion the year before. But the real story is not the market size. It is the regulatory framework that is finally catching up to the technology, opening a path from clinical trials to commercial products.
The Race Neuralink Is Losing
Elon Musk’s Neuralink remains the most famous name in brain-computer interfaces, but it is not the first to market. As of early 2026, Neuralink has enrolled 21 trial participants in its PRIME study, with a target of 30. The company’s invasive approach, which requires open brain surgery to implant a coin-sized chip, faces a longer regulatory pathway than less invasive alternatives.
Synchron, led by CEO Tom Oxley, has taken a different path. Its Stentrode device is implanted through the jugular vein, threading into blood vessels near the brain’s motor cortex without requiring open surgery. Synchron completed its COMMAND early feasibility study with all six patients meeting the primary safety endpoint and is preparing for pivotal trials in 2026. The company raised $200 million in its latest round to accelerate the path to commercial launch.
“We chose the endovascular approach specifically because it maps to a well-understood surgical procedure,” Oxley told IEEE Spectrum. “Every interventional neurologist in the world already knows how to navigate blood vessels in the brain. That dramatically simplifies the path to scale.”
Paradromics received FDA approval for its Connect-One clinical study, targeting chronic speech restoration. The company’s approach uses a high-bandwidth cortical interface with thousands of electrodes, aiming for data rates that could enable natural-speed speech output for patients with paralysis.
The Non-Invasive Consumer Play
The BCI market is bifurcating into two distinct segments with very different timelines and risk profiles.
On one side, clinical-stage invasive BCIs target severe neurological conditions: paralysis, ALS, locked-in syndrome, and treatment-resistant depression. These devices require surgical implantation and carry the regulatory burden that entails.
On the other side, consumer-facing non-invasive neurotechnology is targeting productivity, mental health monitoring, and gaming. Emotiv, the Australian company that has been building EEG headsets for over a decade, introduced MN8 EEG earbuds in 2024, bringing everyday brain-metrics monitoring to a true wireless form factor. The company’s product range spans from the consumer-oriented Insight headset to the professional EPOC Flex, supported by software suites for brain-computer interface control and cognitive performance tracking.
Tan Le, Emotiv’s CEO, has positioned the company as the bridge between clinical neuroscience and consumer electronics. “The brain is the last frontier of the quantified self,” Le said at CES 2026. We have wearables for heart rate, sleep, and activity. Brain activity is next, and it does not require surgery.”
Neurable, a Boston-based startup, has integrated BCI sensors into commercial headphones, targeting office workers who want to track focus and cognitive load throughout the workday. The company’s partnership with a major headphone manufacturer signals that non-invasive BCI is moving from niche to mainstream consumer electronics.
The Regulatory Framework Takes Shape
The FDA published final guidance for implanted BCI devices in 2025, establishing a clear regulatory pathway that covers non-clinical testing requirements, clinical trial design, and post-market surveillance. This was a watershed moment. Previously, BCI companies navigated an ad hoc regulatory process with no standardized framework.
The guidance distinguishes between devices for patients with paralysis or amputation and broader neurological applications, creating tiered requirements based on the invasiveness and intended use of the device. The legal framework is still catching up on questions of neural data privacy, cognitive liberty, and liability for device malfunction.
The intersection of AI and neurotechnology is particularly significant. Modern BCI devices rely heavily on machine learning algorithms to decode neural signals and translate them into device commands. The FDA’s willingness to approve AI-driven medical devices has accelerated the BCI pathway considerably.
What Ships This Fall
Multiple consumer and clinical BCI devices are expected to reach market in the second half of 2026.
Flow Neuroscience’s FL-100, already FDA-approved, is ramping commercial distribution as a prescription device for depression. The device delivers transcranial direct current stimulation guided by an app-based therapy program, and it represents the first time a consumer can receive brain stimulation treatment at home under physician supervision.
Precision Neuroscience is pursuing its first chronic wireless implant, building on the Layer 7 clearance to develop a permanently implanted version of its cortical interface. Synchron’s pivotal trial enrollment across four or more U.S. sites will generate the clinical data needed for a pre-market approval submission.
On the consumer side, the next generation of Emotiv and Neurable devices is expected to ship with significantly improved signal quality and new software capabilities, including real-time cognitive state detection and AI-powered mental health screening.
The Investment Landscape
Venture capital is flowing into BCI at an accelerating rate. Synchron’s $200 million raise was the largest BCI funding round outside of Neuralink. Precision Neuroscience, Paradromics, and several non-invasive BCI startups have raised significant rounds in the past 12 months. The record-setting Q1 2026 venture market included meaningful BCI allocation for the first time.
But the market also faces real challenges. Non-invasive BCI companies like Emotiv face commoditization pressures as the underlying EEG sensor technology becomes cheaper and more accessible. The clinical BCI pathway remains long and expensive, with most companies years away from commercial revenue.
My Take
Brain-computer interfaces are crossing the line from science fiction to regulated medical devices, and the transition is happening faster than most observers expected. The FDA’s decision to establish a clear regulatory framework was the single most important development in the BCI industry’s history, more important than any individual device or clinical trial result.
The companies to watch are not necessarily the ones with the most media attention. Synchron’s endovascular approach solves the biggest barrier to BCI adoption: the requirement for open brain surgery. Precision Neuroscience’s 510(k) clearance demonstrates that the FDA is willing to treat cortical interfaces as a device category, not a one-off exception. And the non-invasive consumer BCI market is about to get very interesting as headphone and earbud manufacturers integrate brain-sensing capabilities into products people already wear.
The first consumer BCI devices shipping this fall will be modest in capability. But they represent the beginning of a technology category that will eventually be as ubiquitous as the fitness tracker. The brain is the last major organ we do not routinely monitor. That is about to change.
